Takeda appoints new CMSO and CCO

To strengthen the Japanese firm as it integrates Nycomed

Japanese drugmaker Takeda has established the new positions of chief medical and scientific officer (CMSO) and chief commercial officer (CCO), to strengthen the company’s governance and business operations as it fully integrates the Nycomed organisation and becomes a global pharmaceutical company.

Dr Tadataka Yamada, a medical doctor and scientist with vast global experience in pharmaceutical r&d and a member of the Takeda board, has been appointed CMSO. The position of chief scientific officer has been abolished.

The new CCO is Dr Frank Morich, also a board member, who will drive sales strategies in the US and EU markets, and also in the fast growing emerging markets. The positions of International Operations (Americas/Europe) and International Operations (North Asia) have been abolished and replaced by the CCO, who will preside over Takeda’s global sales structure (with the exclusion of Millennium and Japanese domestic sales), including most former Nycomed countries and functions.

You may also like

Finance

Takeda Pharmaceutical to acquire GammaDelta Therapeutics

Abingworth was the founding investor in GammaDelta and provided initial seed funding as part of the company’s creation in 2016
Finance

Takeda to evaluate Aptamer Group reagents for drug development

Based on oligonucleotide molecules, Optimers (which the company describes as optimised aptamer reagents) can bind specifically to a target molecule to act as an antibody alternative
Finance

Adaptate Biotherapeutics raises $18 m in Series A2 funding

The financing will also support the company’s expansion, including further recruitment and increased laboratory and office space
Finance

Novadiscovery enters clinical simulation collaboration with Takeda

This agreement builds on an existing relationship between the companies that began in 2017
Research & Development

Evox Therapeutics and Takeda sign multitarget rare disease collaboration

Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox’s proprietary exosome technology
Finance

Charles River secures milestone deals with Takeda and HemaCare

The laboratory giant inks deal with global Japanese drugmaker and completes acquisition of the cell and gene products manufacturer
Media

Only a handful of pharma companies are developing the urgently needed new medicines for the poor

The development of new medical products that are considered the highest priority for people in developing countries is highly concentrated – among five pharmaceutical companies and on five diseases
Subscribe now